Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07621601 Risvutatug Rezetecan Metastatic Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07621601 clinical trial report covering Risvutatug Rezetecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07622121 MHB018A Graves Ophthalmopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07622121 clinical trial report covering MHB018A, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07622108 MHB018A Graves Ophthalmopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07622108 clinical trial report covering MHB018A, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07621796 Tenecteplase Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07621796 clinical trial report covering Tenecteplase, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07620405 MHB018A Graves Ophthalmopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07620405 clinical trial report covering MHB018A, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07623668 Methylprednisolone Optic Neuritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07623668 clinical trial report covering Methylprednisolone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07623824 Octreotide Acetate Acromegaly Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07623824 clinical trial report covering Octreotide Acetate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07623135 Lumateperone Tosylate Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07623135 clinical trial report covering Lumateperone Tosylate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07623798 IBI-3003 Refractory Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07623798 clinical trial report covering IBI-3003, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07624513 Iberdomide Extramedullary Disease in Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07624513 clinical trial report covering Iberdomide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07623915 Bempedoic acid Primary Hyperlipidemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07623915 clinical trial report covering Bempedoic acid, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031260190 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbe Diphtheria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
JPRN-jRCT2031260190 clinical trial report covering Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbe, Phase 3, endpoints, spons